Loretta J. Nastoupil

The University of Texas MD Anderson Cancer Center — United States

Medicine · Health Sciences

59h-index18.4kcitations722works9.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(483), CAR-T cell therapy research(283), Chronic Lymphocytic Leukemia Research(215), Viral-associated cancers and disorders(119), CNS Lymphoma Diagnosis and Treatment(90)

Publications721 total

Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop
Blood Advances·2025Open Access
FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma
Journal of Clinical Oncology·2025Open Access
Clinical trial success rate in lymphoma: fate of trials and agents from 2000 to 2019
Blood Advances·2025Open Access
FLP-R: A clinical prediction model for follicular lymphoma Prognosis in the Relapsed/refractory setting
Blood·2025Open Access
Shorter diagnosis to treatment interval is associated with poor prognosis in patients with peripheral T-cell lymphoma: Analysis from the LEO and MER cohorts
Blood·2025
A Phase 1 study of KITE-753 or KITE-363 in patients with relapsed/refractory B-cell lymphoma: Initial safety and preliminary efficacy of KITE-753 and updated results of KITE-363
Blood·2025Open Access
Patterns of care and outcomes in patients with large B-cell lymphoma not treated with full-dose anthracycline regimens: Outcome analysis from the lymphoma epidemiology of outcomes (LEO) prospective cohort study
Blood·2025Open Access
Impact of putative cell of origin on CD19+CAR-T outcomes in patients with large B-cell lymphoma
Blood·2025Open Access
Outcomes of CAR T-cell therapies after prior treatment with fixed-duration mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
Blood·2025
Clinical outcomes of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (r/r FL): Phase 2 ELARA 5-year update
Blood·2025
Outcomes of tafasitamab and lenalidomide in large B‐cell lymphoma based on prior CD19‐directed CAR T exposure
HemaSphere·2025Open Access
Adaptation and Performance of the Self‐Report‐Generated Charlson Comorbidity Index in the Lymphoma Epidemiology of Outcomes (LEO) Cohort
Hematological Oncology·2025
POSTER: IBCL-1109 Golcadomide, a CELMoD Agent, With or Without Rituximab in Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL): Updated Phase 1/2 Results
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: IBCL-1066 ELARA Phase 2 Clinical Outcomes for Tisagenlecleucel in Patients With High-Risk Relapsed/Refractory Follicular Lymphoma: 4-Year Update
Clinical Lymphoma Myeloma & Leukemia·2025
ABCL-1115: Golcadomide, a Cereblon E3 Ligase Modulator (CELMoD) Agent, With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Updated Phase 1/2 Results
Clinical Lymphoma Myeloma & Leukemia·2025· 1 cited
IBCL-1066: ELARA Phase 2 Clinical Outcomes for Tisagenlecleucel in Patients With High-Risk Relapsed/Refractory Follicular Lymphoma: 4-Year Update
Clinical Lymphoma Myeloma & Leukemia·2025
ORAL ABSTRACT: CT-230 Lisocabtagene Maraleucel (liso-cel) in Patients With Relapsed or Refractory (R/R) Marginal Zone Lymphoma (MZL) in the Phase 2 TRANSCEND FL Study
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: ABCL-1115 Golcadomide, a Cereblon E3 Ligase Modulator (CELMoD) Agent, With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Updated Phase 1/2 Results
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: CT-230 Lisocabtagene Maraleucel (liso-cel) in Patients With Relapsed or Refractory (R/R) Marginal Zone Lymphoma (MZL) in the Phase 2 TRANSCEND FL Study
Clinical Lymphoma Myeloma & Leukemia·2025
CT-230: Lisocabtagene Maraleucel (liso-cel) in Patients With Relapsed or Refractory (R/R) Marginal Zone Lymphoma (MZL) in the Phase 2 TRANSCEND FL Study
Clinical Lymphoma Myeloma & Leukemia·2025
page 1 of 37Next →

Frequent Co-authors

Sattva S. Neelapu(23), Jason R. Westin(21), Christopher R. Flowers(21), Nathan Fowler(19), Luis Fayad(18), Michael Wang(14), Felipe Samaniego(13), Hun Ju Lee(12), Maria Alma Rodriguez(11), Sairah Ahmed(11), Yasuhiro Oki(10), Paolo Strati(9), Fredrick B. Hagemeister(9), Chelsea C. Pinnix(9), Jorge Romaguera(8), Ranjit Nair(8), Swaminathan P. Iyer(8), Matthew A. Lunning(7), Joseph P. McGuirk(7), Michael R. Green(7)